Due to the risk of T2DM in cardiovascular conditions, the differences between groups regarding the frequency of cardiovascular comorbidities or the consumption of aspirin, ACE inhibitors (ACEIs), and beta-blockers are not surprising. This evidence concerns the gene ACE and type 2 diabetes mellitus.